Long-term outcome of Hurler syndrome following bone marrow transplantation
- PMID: 8484412
- DOI: 10.1002/ajmg.1320460222
Long-term outcome of Hurler syndrome following bone marrow transplantation
Abstract
Previous reports suggested a therapeutic response of lysosomal storage diseases such as Hurler syndrome following bone marrow transplantation. However, a clearer understanding of outcome has awaited long-term follow-up. We evaluated prospectively 11 consecutive patients with Hurler syndrome receiving marrow from an HLA-identical sib donor between September 1983-October 1988. Follow-up evaluations included assessment of donor engraftment by restriction fragment polymorphism analysis, determination of leukocyte alpha-L-iduronidase level, measurement of lumbar cerebrospinal fluid (CSF) pressure, computerized tomography (CT) of the brain, and psychometric testing. In this series there was a survival rate of 9/11 (82%) with all survivors showing complete (7 patients) or partial (2 patients) donor engraftment. Prospective longitudinal evaluation of the 9 surviving children, now 3.8-8.9 years posttransplantation (median 5.5) demonstrated persistence of previously deficient leukocyte alpha-L-iduronidase at levels reflecting the donor genotype and degree of donor engraftment. Urinary glycosaminoglycan excretion declined to near-normal within 5 months of donor engraftment. Prior to treatment, 7 of 8 children studied were found to have occult intracranial hypertension (lumbar CSF pressure > 20 cm CSF); however, all surviving children attained normal or near-normal pressure within 18 months of donor engraftment. Longterm follow-up CT imaging of the brain did not show progressive volume loss (cerebral atrophy) after donor engraftment. Of 9 survivors, 4 children having a developmental quotient (DQ, Mental Development Index on Bayley Scales of Infant Development) above 80 prior to transplantation subsequently maintained IQ scores above this level. However, 5 patients with lower pretransplant DQ scores now have significant cognitive deficits and attention deficit hyperactivity disorder. Progressive brain damage resulting from communicating hydrocephalus may be prevented by successful engraftment. Early transplantation of children with Hurler syndrome who have normal intelligence is likely to have the clearest benefit because long-term intellectual outcome will be limited by brain damage which has occurred prior to treatment.
Similar articles
-
Outcome of second hematopoietic cell transplantation in Hurler syndrome.Bone Marrow Transplant. 2002 Mar;29(6):491-6. doi: 10.1038/sj.bmt.1703395. Bone Marrow Transplant. 2002. PMID: 11960268
-
Hurler syndrome: II. Outcome of HLA-genotypically identical sibling and HLA-haploidentical related donor bone marrow transplantation in fifty-four children. The Storage Disease Collaborative Study Group.Blood. 1998 Apr 1;91(7):2601-8. Blood. 1998. PMID: 9516162 Clinical Trial.
-
Outcome of unrelated donor bone marrow transplantation in 40 children with Hurler syndrome.Blood. 1996 Jun 1;87(11):4894-902. Blood. 1996. PMID: 8639864 Clinical Trial.
-
Life-threatening pulmonary hemorrhages post bone marrow transplantation in Hurler syndrome. Report of three cases and review of the literature.Bone Marrow Transplant. 2003 Jul;32(2):213-5. doi: 10.1038/sj.bmt.1704115. Bone Marrow Transplant. 2003. PMID: 12838287 Review.
-
Unexpected coronary artery findings in mucopolysaccharidosis. Report of four cases and literature review.Cardiovasc Pathol. 2014 May-Jun;23(3):145-51. doi: 10.1016/j.carpath.2014.01.001. Epub 2014 Jan 10. Cardiovasc Pathol. 2014. PMID: 24508139 Review.
Cited by
-
Metabolic correction and cross-correction of mucopolysaccharidosis type II (Hunter syndrome) by retroviral-mediated gene transfer and expression of human iduronate-2-sulfatase.Proc Natl Acad Sci U S A. 1993 Dec 15;90(24):11830-4. doi: 10.1073/pnas.90.24.11830. Proc Natl Acad Sci U S A. 1993. PMID: 8265633 Free PMC article.
-
Increased longevity and metabolic correction following syngeneic BMT in a murine model of mucopolysaccharidosis type I.Bone Marrow Transplant. 2012 Sep;47(9):1235-40. doi: 10.1038/bmt.2011.239. Epub 2011 Dec 19. Bone Marrow Transplant. 2012. PMID: 22179554 Free PMC article.
-
Nonviral in vivo gene transfer in the mucopolysaccharidosis I murine model.J Inherit Metab Dis. 2005;28(6):1035-43. doi: 10.1007/s10545-005-0070-5. J Inherit Metab Dis. 2005. PMID: 16435197
-
Gene therapy for neurologic manifestations of mucopolysaccharidoses.Expert Opin Drug Deliv. 2015 Feb;12(2):283-96. doi: 10.1517/17425247.2015.966682. Epub 2014 Dec 16. Expert Opin Drug Deliv. 2015. PMID: 25510418 Free PMC article. Review.
-
Prolonged expression of a lysosomal enzyme in mouse liver after Sleeping Beauty transposon-mediated gene delivery: implications for non-viral gene therapy of mucopolysaccharidoses.J Gene Med. 2007 May;9(5):403-15. doi: 10.1002/jgm.1028. J Gene Med. 2007. PMID: 17407189 Free PMC article.
Publication types
MeSH terms
Substances
Grants and funding
LinkOut - more resources
Full Text Sources
Other Literature Sources
Medical
Research Materials